Gentronix Limited, a company spun-out of The University of Manchester by its technology transfer company UMIP, announced today that it has entered into an agreement to provide GlaxoSmithKline (GSK) with its novel genotoxicity detection assay GreenScreen HC.
GreenScreen HC is the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay is amenable to high throughput screening, provides additional data for safety profiling, consumes very low quantities of compound and gives rapid results.
The proprietary reporter based assay detects all known classes of genotoxic agent and utilizes Green Fluorescent Protein in order to detect GADD-45a up-regulation which is a key indicator of DNA damage.
John Nicholson, CEO and Chairman of Gentronix said ‘we have worked with GSK previously on the early validation of our technology and are delighted that they will be incorporating GreenScreen HC into their safety evaluation activities. This agreement provides important validation of our technology and demonstrates the value we bring to our customers.’
Financial terms of the agreement were not released.
Gentronix provides services and solutions that help companies reduce attrition rates and ensure safer products across a wide range of chemistry driven industries. Our primary focus is on providing better hazard identification assays for genotoxicity through use of GreenScreen(R) human cell assay technology. GreenScreen HC and HC S9 assays are designed for use much earlier in drug and compound discovery than the standard battery of genotoxicity tests and provide positive results that are more accurately predictive of in vivo risk than the current in vitro mammalian assays. To find out more about our products and services please visit our website www.gentronix.co.uk or contact us at firstname.lastname@example.org